[AF] topiramato y bulimia compulsiva

m.carmen Gonzalez mcgonru10 en yahoo.es
Mar Sep 30 10:29:00 CEST 2003

Perdon, esto también.

ARTICLE TITLE:  Topiramate in the treatment of binge
eating disorder associated with obesity: a randomized,
placebo-controlled trial. 
COMMENTS:  Erratum In: Erratum In: RefSource:Am J
Psychiatry. 2003 Mar; 160(3):612 
ARTICLE SOURCE:  Am J Psychiatry  (United States), Feb
2003, 160(2) p255-61 
AUTHOR(S):  McElroy SL; Arnold LM; Shapira NA; Keck
PE; Rosenthal NR; Karim MR; Kamin M; Hudson JI 
AUTHOR'S ADDRESS:  Division of Psychopharmacology
Research, Department of Psychiatry, University of
Cincinnati College of Medicine, OH 45267-0559, USA.
susan.mcelroy en uc.edu. 
MAJOR SUBJECT HEADING(S):  Anticonvulsants
[therapeutic use]; Bulimia [drug therapy]; Fructose
[analogs & derivatives] [therapeutic use]; Obesity
Anticonvulsants [administration & dosage]; Bulimia
[epidemiology]; Comorbidity; Double-Blind Method; Drug
Administration Schedule; Fructose [administration &
dosage]; Obesity [epidemiology]; Placebos; Treatment
INDEXING CHECK TAG(S):  Human; Support, Non-U.S. Gov't

PUBLICATION TYPE:  Owner: NLM; Status: Completed 
Clinical Trial; Journal Article; Randomized Controlled
ABSTRACT:  OBJECTIVE: Binge eating disorder is
associated with obesity. Topiramate is an
antiepileptic agent associated with weight loss. The
objective of this study was to evaluate topiramate in
the treatment of binge eating disorder associated with
obesity. METHOD: For this 14-week, double-blind,
flexible-dose (25-600 mg/day) topiramate trial, 61
outpatients (53 women, eight men) with binge eating
disorder who were obese (body mass index >/=30
kg/m(2)) were randomly assigned to receive topiramate
(N=30) or placebo (N=31). The primary efficacy measure
was binge frequency. The primary analysis of efficacy
was a repeated-measures random regression with
treatment-by-time as the effect measure. RESULTS:
Compared with placebo, topiramate was associated with
a significantly greater rate of reduction in binge
frequency, binge day frequency, body mass index,
weight, and scores on the Clinical Global Impression
severity scale and the Yale-Brown Obsessive Compulsive
Scale (modified for binge eating). Topiramate was also
associated with significantly greater reductions in
binge frequency (topiramate: 94%, placebo: 46%) and
binge day frequency (topiramate: 93%, placebo: 46%)
and with a significantly higher level of response than
placebo. The mean weight loss for topiramate-treated
subjects who completed the study was 5.9 kg. Median
topiramate dose was 212 mg/day (range=50-600). Nine
patients (three receiving placebo, six given
topiramate) discontinued because of adverse events.
The most common reasons for discontinuing topiramate
were headache (N=3) and paresthesias (N=2).
CONCLUSIONS: Topiramate was efficacious and relatively
well tolerated in the short-term treatment of binge
eating disorder associated with obesity. 
ISSN:  0002-953X 
LANGUAGE:  English 
CAS REGISTRY/EC NUMBER(S):   0 (Anticonvulsants); 0
(Placebos); 30237-26-4 (Fructose); 97240-79-4

Yahoo! Messenger - Nueva versión GRATIS
Super Webcam, voz, caritas animadas, y más...

Más información sobre la lista de distribución AF